相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?
Ernesto Rossi et al.
CURRENT ONCOLOGY REPORTS (2021)
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials
Francesco Massari et al.
EUROPEAN JOURNAL OF CANCER (2021)
Therapeutic Drug Monitoring of Sunitinib in Gastrointestinal Stromal Tumors and Metastatic Renal Cell Carcinoma in Adults-A Review
Regina Demlova et al.
THERAPEUTIC DRUG MONITORING (2020)
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
Maria Krchniakova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial
Arnauld C. Verschuur et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
A Case of Cobalamin Deficiency and Macrocytic Anemia Secondary to Sunitinib
Jarred P. Reed et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2019)
Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice
Alexandr Poprach et al.
DRUGS & AGING (2016)
Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment
Jacqueline S. L. Kloth et al.
EUROPEAN JOURNAL OF CANCER (2016)
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
Jakub Kucharz et al.
MEDICAL ONCOLOGY (2016)
Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma
Maria T. Bourlon et al.
CANCER MEDICINE (2016)
Inhibition of c-Kit by tyrosine kinase inhibitors
Allison Galanis et al.
HAEMATOLOGICA (2015)
Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours
I Kocakova et al.
BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY (2015)
Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis
Ezzeldin M. Ibrahim et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study
Steven G. DuBois et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study
Steven G. DuBois et al.
CLINICAL CANCER RESEARCH (2011)
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib
Alfredo Carrato Mena et al.
ANTI-CANCER DRUGS (2010)
Sunitinib causes macrocytosis in patients with advanced renal cell carcinoma
L. Wood et al.
Current Oncology (2010)
Pharmacokinetics of sunitinib in hemodialysis
H. Izzedine et al.
ANNALS OF ONCOLOGY (2009)
A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
Brett E. Houk et al.
CLINICAL CANCER RESEARCH (2009)
Sunitinib Treatment in Pediatric Patients With Advanced GIST Following Failure of Imatinib
Katherine A. Janeway et al.
PEDIATRIC BLOOD & CANCER (2009)
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma
Brian I. Rini et al.
CANCER (2008)
Macrocytosis and cobalamin deficiency in patients treated with sunitinib
Silke Gillessen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Estimating regression models with unknown break-points
VMR Muggeo
STATISTICS IN MEDICINE (2003)
分享论文
